<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283608</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000583001</org_study_id>
    <secondary_id>MC0532</secondary_id>
    <secondary_id>999-05</secondary_id>
    <nct_id>NCT00283608</nct_id>
    <nct_alias>NCT00366054</nct_alias>
  </id_info>
  <brief_title>Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer</brief_title>
  <official_title>Pharmacogenetics of Aromatase Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving&#xD;
      anastrozole may help doctors learn more about changes that occur in DNA and identify&#xD;
      biomarkers related to cancer. It may also help doctors learn more about how anastrozole works&#xD;
      in the body.&#xD;
&#xD;
      PURPOSE: This research study is looking at the pharmacogenetics of anastrozole in&#xD;
      postmenopausal women with estrogen receptor-positive (ER+) and/or progesterone&#xD;
      receptor-positive (PR+) stage I, stage II, or stage III breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To evaluate the association of intragenic haplotypes in genes encoding proteins involved&#xD;
           in anastrozole metabolism pathways with anastrozole steady state plasma levels in&#xD;
           postmenopausal women with estrogen receptor-positive and/or progesterone&#xD;
           receptor-positive stage I, II, or III breast cancer.&#xD;
&#xD;
        -  To evaluate the association of intragenic haplotypes in genes that encode proteins&#xD;
           involved in pathways for estrogen synthesis, metabolism, and transport and in genes&#xD;
           involved in anastrozole metabolism with the pharmacodynamic (PD) effects of anastrozole&#xD;
           therapy, as measured by changes (before vs after drug therapy) in plasma levels of&#xD;
           estradiol, estrone, estrone sulfate, testosterone, and androstenedione in these&#xD;
           patients.&#xD;
&#xD;
        -  To evaluate the association of intragenic haplotypes described above with the PD effects&#xD;
           of anastrozole therapy, as measured by changes in breast density and bone mineral&#xD;
           density before and at 1 year after drug therapy.&#xD;
&#xD;
        -  To collect and bank blood samples and mammographic, bone density, and questionnaire data&#xD;
           from patients enrolled on CAN-NCIC-MA27 and randomized to receive exemestane.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to prior tamoxifen&#xD;
      use (yes vs no).&#xD;
&#xD;
      Blood samples are obtained for pharmacogenetic studies at baseline, at 6-12 weeks, and then&#xD;
      at 1 year. Samples are analyzed for plasma anastrozole concentrations via high-performance&#xD;
      liquid chromatography; genotyping for htSNPs via PCR; plasma levels of estradiol, estrone,&#xD;
      estrone sulfate, testosterone, and androstenedione via gas chromatographic negative chemical&#xD;
      ionization tandem mass spectrometry and liquid chromatographic electrospray tandem mass&#xD;
      spectrometry.&#xD;
&#xD;
      Mammograms are obtained at baseline (i.e., within the past 6 months) and at 1 year to assess&#xD;
      breast density. Patients with bilateral disease, bilateral breast augmentation, or bilateral&#xD;
      mastectomy do not participate in this portion of the study.&#xD;
&#xD;
      Patients at the Mayo Clinic Cancer Center Rochester site also undergo bone mineral density&#xD;
      measurement via dual x-ray absorptiometry at baseline and at 1 year. Metabolic markers of&#xD;
      bone formation and resorption are also assessed in the Mayo Clinic patients.&#xD;
&#xD;
      Blood samples and mammographic, bone mineral density, and questionnaire data collected from&#xD;
      patients randomized to receive exemestane on CAN-NCIC-MA27 are stored for future studies.&#xD;
&#xD;
      Patients complete a questionnaire at baseline, at 6-12 weeks, and at 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association of single nucleotide polymorphisms with specific quantitative traits (i.e., hormone levels, breast density, and bone mineral density)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Association of haplotype with traits</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of genomic pathways with traits</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <description>Blood draws for baseline and six to twelve weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exemestane</arm_group_label>
    <description>Blood draws for baseline and six to twelve weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Single nucleotide polymorphism (SNP)</intervention_name>
    <description>Evaluating SNP association with traits.</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_label>Exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
    <description>analysis of plasma concentrations of drugs</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_label>Exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>measurements by DXA</intervention_name>
    <description>determine bone mineral density (BMD)</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_label>Exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>determine attitude changes</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_label>Exemestane</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Anastrozole treatment group samples will be used as described for this study, and then will&#xD;
      be destroyed.&#xD;
&#xD;
      Exemestane treatment group samples of blood will be stored at Mayo Clinic Rochester.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosis of breast cancer. Stage I, II, or III disease.&#xD;
&#xD;
        Planning to undergo treatment with anastrozole at the clinically approved dose of 1 mg/day&#xD;
        OR Mayo Clinic Cancer Center Rochester patient who will be enrolled on or has been enrolled&#xD;
        on CAN-NCIC-MA27 and has not started taking the study medication (anastrozole or&#xD;
        exemestane)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of breast cancer&#xD;
&#xD;
               -  Stage I, II, or III disease&#xD;
&#xD;
               -  Resected disease&#xD;
&#xD;
          -  Planning to undergo treatment with anastrozole at the clinically approved dose of 1&#xD;
             mg/day OR Mayo Clinic Cancer Center Rochester patient who will be enrolled on or has&#xD;
             been enrolled on CAN-NCIC-MA27 and has not started taking the study medication&#xD;
             (anastrozole or exemestane)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor-positive and/or progesterone receptor-positive primary tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
          -  Able to complete questionnaires alone or with assistance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 6 months since prior endocrine therapy, except tamoxifen&#xD;
&#xD;
          -  No other prior aromatase inhibitors (e.g., letrozole or exemestane)&#xD;
&#xD;
          -  No prior ovarian function suppression with surgery or radiotherapy, ovarian ablation,&#xD;
             or luteinizing hormone-releasing hormone analogues (e.g., goserelin) as treatment for&#xD;
             cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James N. Ingle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edith A. Perez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald W. Northfelt, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 2010 Apr 15;70(8):3278-86. doi: 10.1158/0008-5472.CAN-09-3024. Epub 2010 Mar 30.</citation>
    <PMID>20354183</PMID>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>January 27, 2006</study_first_submitted>
  <study_first_submitted_qc>January 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2006</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>James N. Ingle, M.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

